The protective effect of probiotic therapy on gut microbiota and the activation of ω-oxidation after ovarian cancer surgery Authors: Chen Geng, Qingling Cao, Zhuo Chen, Xiaoyan Song, Xiaoyuan Shi Published: 2025 ABSTRACT PurposePostoperative gut dysbiosis and inflammation are common complications in ovarian cancer patients. This study aims to investigate the protective role of probiotic therapy on gut microbiota homeostasis and its potential mechanism via activation of the ω-oxidation pathway.MethodsWe conducted a clinical analysis of ovarian cancer patients post-surgery who received probiotic therapy. Fecal samples were collected and analyzed using 16S rRNA sequencing to determine microbial diversity and composition. Metabolic pathway analysis was performed via MetaCyc. Additionally, an ovarian cancer mouse model was established to evaluate intestinal permeability, inflammatory cytokine levels, histopathological changes, and expression of ω-oxidation-related genes and proteins. The role of short-chain fatty acids (SCFAs) was also examined through combined administration with probiotics.ResultsProbiotic treatment significantly restored gut microbial diversity and reduced dysbiosis in post-surgical ovarian cancer patients. 16S rRNA sequencing revealed increased abundance of beneficial genera such as Alistipes, Roseburia, and Ruminococcus, while metabolic pathway analysis indicated significant activation of the ω-oxidation pathway. In mice, probiotic treatment reduced FD4 levels, restored intestinal barrier function, and modulated inflammatory cytokines by increasing IL-4 and IL-10 and decreasing IL-6 and TNF-α. Furthermore, probiotics upregulated expression of PPARα, CYP4F3, and CYP4A10 at both mRNA and protein levels, while reducing ROS and MDA levels, indicating alleviated oxidative stress. Combined treatment with SCFAs further enhanced these effects, suggesting a synergistic activation of ω-oxidation signaling and better restoration of gut homeostasis.ConclusionProbiotic therapy effectively restores gut microbiota composition and intestinal integrity following ovarian cancer surgery, potentially through activation of the ω-oxidation pathway.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00432-025-06398-1. Introduction Ovarian cancer remains one of the most lethal gynecological malignancies worldwide, with surgical intervention being a critical component of treatment (Wei et al. 2024). However, postoperative complications such as gut dysbiosis and intestinal inflammation frequently occur, impairing patient recovery and quality of life (Güngördük et al. 2017; Voitk et al. 1972). The gut microbiota plays a pivotal role in maintaining intestinal homeostasis, modulating immune responses, and influencing systemic metabolism (Vincenzo et al. 2024). Disruption of this delicate microbial ecosystem after surgery can exacerbate inflammation and compromise the intestinal barrier, leading to increased permeability and heightened risk of infection (Gasmi et al. 2023). Probiotic therapy has emerged as a promising approach to restore gut microbial balance and improve intestinal health in various clinical contexts, including cancer (Redenti et al. 2024). Probiotics, primarily composed of beneficial bacteria such as Lactobacillus and Bifidobacterium, can enhance barrier integrity, modulate inflammatory cytokines, and suppress pathogenic microorganisms (Badgeley et al. 2021). Several studies have demonstrated the protective effects of probiotics in reducing postoperative infections and promoting gut homeostasis (Chen et al. 2020). Nonetheless, the underlying molecular mechanisms through which probiotics exert these beneficial effects, particularly after ovarian cancer surgery, remain incompletely understood. Recent evidence suggests that metabolic pathways regulated by the gut microbiota may contribute significantly to intestinal health. Among these, the ω-oxidation pathway—a specialized fatty acid oxidation process catalyzed by enzymes such as cytochrome P450 family members (Zhao et al. 2025) and regulated by the nuclear receptor PPARα—has been implicated in maintaining lipid metabolism and reducing oxidative stress (Kong et al. 2021). Activation of this pathway may mitigate inflammation-induced tissue damage and promote recovery of the intestinal barrier. Furthermore, SCFAs, key microbial metabolites derived from dietary fiber fermentation, are known to influence host metabolism and immune responses, potentially synergizing with probiotics to enhance ω-oxidation signaling (Parada Venegas et al. 2019; Kam et al. 1978). In this study, we aimed to investigate the protective role of probiotic therapy in restoring gut microbiota homeostasis in ovarian cancer patients following surgery and to explore the potential mechanism involving the activation of the ω-oxidation pathway. Using clinical samples and an ovarian cancer mouse model, we evaluated changes in microbial diversity, intestinal permeability, inflammatory cytokine profiles, and expression of key ω-oxidation-related genes and proteins. Additionally, we examined the synergistic effects of combining probiotics with SCFAs to provide insight into novel therapeutic strategies for enhancing postoperative recovery. Method and materials Patient collection Ovarian cancer patients hospitalized at Suqian First People’s Hospital and undergoing surgical treatment were enrolled in this study from December 2023 to June 2025,. All participants met the predefined inclusion and exclusion criteria, signed informed consent forms prior to enrollment, and were assured of confidentiality and data privacy. The study protocol was reviewed and approved by the Ethics Committee of Suqian First People’s Hospital.Inclusion criteria were as follows: (1) Female patients aged 30–70 years, newly diagnosed with epithelial ovarian cancer in accordance with the Diagnostic and Therapeutic Guidelines for Epithelial Ovarian Cancer (2018 edition); (2) Histopathologically confirmed diagnosis of ovarian cancer requiring surgical resection; (3) No evidence of widespread distant metastases; (4) Provision of written informed consent.Exclusion criteria included: (1) Use of antibiotics, prebiotics, probiotics, or synbiotics within two weeks prior to enrollment; (2) Presence of metabolic disorders (e.g., diabetes mellitus) or severe comorbidities involving the heart, lungs, liver, or kidneys; (3) Family history of colorectal cancer or other gastrointestinal malignancies; (4) Known allergies to study medications or conditions such as pregnancy; (5) Coexisting primary gastrointestinal diseases (e.g., Crohn’s disease, ulcerative colitis, or gastrointestinal tumors). Eligible patients received oral probiotic treatment postoperatively, beginning with the resumption of oral intake. Patients were administered probiotic tablets (one tablet per dose, three times daily) for a duration of seven consecutive days. Postoperative ovarian cancer mouse model SPF grade female BALB/c mice, aged 6–8 weeks and weighing 18–22 g, were obtained from the SPF-grade Laboratory Animal Center. An intraperitoneal injection of 5 × 106 ID8-Luc mouse ovarian cancer cells per mouse was administered to establish the ovarian cancer model. Mice were monitored for 7–14 days post-injection to ensure stable tumor establishment. Once tumor growth was confirmed, mice underwent simulated postoperative intervention. Prior to surgery, mice were anesthetized with isoflurane and subjected to bilateral ovariectomy (OVX) to mimic surgical tumor resection (Zhai et al. 2025). During the procedure, the surgical area was irrigated with sterile saline, and incisions were carefully sutured. Postoperatively, mice were placed in a suitable recovery environment and monitored for general health status. Mice without apparent postoperative complications proceeded to the next phase of the experiment. Following the recovery period, probiotic intervention was initiated. Mice received daily oral gavage of probiotics at a concentration of 1 × 108 CFU/mouse for 4–6 weeks. At the end of the intervention, mice were fasted for 12 h, then anesthetized and humanely euthanized for subsequent sample collection and analysis. 16S rRNA sequencing Fecal samples stored at − 80 °C were thawed at room temperature. Approximately 200 mg of fecal material was transferred into sterile centrifuge tubes for DNA extraction. Total microbial DNA was extracted using a standard stool DNA extraction protocol, followed by quality control assessment to ensure DNA integrity and purity. The V4 region of the 16S rRNA gene was amplified via PCR and purified. Sequencing libraries were then constructed and subjected to high-throughput sequencing. Microbial community analysis was conducted using QIIME2 and the DADA2 pipeline. Alpha (α) diversity, beta (β) diversity, and differences in microbial community structure between samples were assessed to evaluate richness, evenness, and compositional variation. Functional predictions of the microbial communities were performed using PICRUSt2. Metabolic pathway analyses, including primary and secondary metabolic functions and associated metabolites, were conducted using the MetaCyc database. FD4 assay for intestinal permeability Mice were administered FD4 (fluorescein isothiocyanate–dextran, 4 kDa) via oral gavage at a dose of 600 mg/kg body weight. After 4 h, blood samples were collected via orbital puncture, and serum was isolated by centrifugation. Serum FD4 concentrations were measured using a fluorescence microplate reader at an excitation/emission wavelength of 485/525 nm. Quantitative analysis was performed based on a standard curve generated from known FD4 concentrations. ELISA Blood and intestinal tissue samples were collected from mice. Blood samples were centrifuged at 1800 rpm to separate serum. Intestinal tissues were homogenized, and the supernatant from the homogenates was collected. Both serum and tissue homogenate supernatants were allowed to equilibrate at room temperature for 1 h, followed by centrifugation at 5000 rpm for 15 min at 4 °C using a refrigerated centrifuge. The resulting supernatants were collected as experimental samples and stored at − 80 °C until analysis.According to the manufacturers’ protocols, 100 µL of appropriately diluted samples were added to the reaction wells for the detection of MDA (Elabscience, E-EL-0060), IL-4 (Beyotime, PI612), IL-10 (Beyotime, PI525), IL-6 (Beyotime, PI326), and TNF-α (Spbio, SP13726). Subsequently, 100 µL of standards and 100 µL of biotin-labeled antibodies were added to each well, followed by incubation at 37 °C for 1.5 h. After washing the wells three times, streptavidin–horseradish peroxidase conjugate was added, and the plate was incubated for an additional 45 min at 37 °C. Washing steps were repeated as above. Finally, TMB substrate solution was added and incubated for 10 min at room temperature in the dark. The reaction was stopped by adding stop solution, and absorbance was measured immediately using a multifunctional microplate reader. H&E staining Mouse intestinal tissues fixed in 4% paraformaldehyde were subjected to dehydration, paraffin embedding, sectioning, and drying. Sections were deparaffinized in xylene, rehydrated through a graded ethanol series to water, and stained sequentially with hematoxylin and eosin solutions. Following staining, sections were dehydrated through graded ethanol, cleared in xylene, and mounted with neutral resin. Histopathological changes in colon tissues were analyzed by examining multiple fields of view under a light microscope for each section. qPCR Mouse intestinal tissues were collected and total RNA was extracted using the Trizol reagent according to the manufacturer’s protocol. Extracted RNA samples were stored at − 80 °C. RNA concentration and purity were assessed by UV spectrophotometry at wavelengths of 260 and 280 nm, with an absorbance ratio (A260/A280) ranging from 1.7 to 2.2, indicating high purity. Reverse transcription was performed using the Takara kit in a 10 µL reaction system under the following conditions: 37 °C for 15 min and 85 °C for 5 s. The resulting cDNA products were stored at 4 °C prior to real-time PCR. Quantitative PCR was conducted using SYBR Premix Ex Taq™ reagent. The amplification protocol included an initial denaturation at 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 20 s (annealing), 72 °C for 20 s (extension), and 78 °C for 20 s. Each sample was run in triplicate, and fluorescence data were collected at each cycle. Relative expression levels of miR-34a were calculated using the 2^−ΔΔCt method. Primer sequences are listed as follows: PPARα:F-5′-AACATCGAGTGTCGAATATGTGG-3′; R-5′-CCGAATAGTTCGCCGAAAGAA-3′;CYP4F3:F-5′-CATCCGTTTTTGCCACCCC-3′;R-5′-GACGGGCATACCCTTTTGAGG-3′;CYP4A10:F-5′-TTCCCTGATGGACGCTCTTTA-3′;R-5′-GCAAACCTGGAAGGGTCAAAC-3′;GAPDH: F-5′-AGGTCGGTGTGAACGGATTTG-3′;R-5′-GGGGTCGTTGATGGCAACA-3′. Western blot Mouse intestinal tissues were homogenized on ice in RIPA lysis buffer supplemented with PMSF and protease inhibitor cocktail. The homogenates were centrifuged at 12,000×g for 10 min at 4 °C, and the supernatants were collected as total protein extracts. Proteins were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, membranes were incubated overnight at 4 °C with primary antibodies against PPARα (Proteintech, 66826-1-Ig), CYP4F3 (Proteintech, 19701-1-AP), and CYP4A10 (Abcam, ab3573) diluted 1:1000 in blocking buffer. After washing with TBST, membranes were incubated with HRP-conjugated secondary antibodies (1:10,000) at room temperature for 60 min. Following repeated TBST washes, protein bands were visualized using chemiluminescence and quantified for analysis. ROS detection Mouse intestinal tissues were collected and mechanically dissociated to prepare a single-cell suspension. The resulting cell pellets were fixed by adding 1 mL of pre-cooled 4% paraformaldehyde, gently pipetting to mix, and incubating at 4 °C for at least 2 h. After fixation, cells were centrifuged at 1000×g for 3–5 min at 4 °C, and the supernatant was discarded. Cells were then incubated with DCFH-DA diluted in serum-free medium or PBS to a final concentration of 5–10 µM, protected from light, at 37 °C for 20–30 min. Following incubation, the probe solution was removed, and cells were washed twice with PBS. Fluorescence intensity of each sample was analyzed using flow cytometry. Data were processed and analyzed using FlowJo software. Statistical analysis All experimental data were expressed as mean ± standard deviation (mean ± SD). Statistical analyses were performed using GraphPad Prism 8.0 software. Comparisons between two groups were conducted using Student’s t-test, while multiple group comparisons were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. p < 0.05 was considered statistically significant. Results Probiotic treatment restores intestinal homeostasis in ovarian cancer patients after surgery Initially, We collected clinical samples from postoperative ovarian cancer patients who received probiotic treatment. Subsequently, fecal samples were collected from these patients for analysis of the gut microbiota composition and species richness using 16S rRNA sequencing. Comparative analyses of microbial composition before and after treatment were conducted at both the phylum and genus levels. At the phylum level, significant changes post-probiotic treatment were observed primarily in Gemmatimonadetes, Therm, Elusimicrobia, Fusobacteria, and Synergistetes, among others (Fig. 1A). At the genus level, compared to pre-treatment samples, probiotic administration led to significant alterations in the relative abundance of Alistipes, Oscillospira, Dorea, Actinomyces, Eubacterium, Roseburia, Enterococcus, Eggerthella, and Ruminococcus (Fig. 1B). Alpha diversity analysis revealed that probiotic treatment resulted in a more concentrated microbial community composition and distribution relative to pre-treatment conditions (Fig. S1A). Furthermore, beta diversity analysis demonstrated substantial differences in community structure within the probiotic-treated group, as evidenced by distinct separation in the PCoA plot (Fig. S1B). These findings suggest that probiotic intervention may promote the enrichment of specific beneficial bacteria such as Lactobacillus and Bifidobacterium, while concurrently inhibiting the growth of pathogenic or non-target microorganisms. Fig. 1Phylum-level (A) and genus-level (B) composition and differential analysis of gut microbiota in patients before and after probiotic treatment. BT, Before Treatment; AT, After Treatment Phylum-level (A) and genus-level (B) composition and differential analysis of gut microbiota in patients before and after probiotic treatment. BT, Before Treatment; AT, After Treatment To further elucidate the potential molecular mechanisms underlying probiotic treatment, MetaCyc metabolic pathway analysis was performed. The results indicated that biosynthetic metabolic pathways exhibited the most significant differences, notably in amino acid metabolism, fatty acid and lipid biosynthesis, and nucleotide metabolism (Fig. 2A). Additionally, detailed metabolic pathway analysis identified the P221-PWY ω-oxidation pathway as potentially playing a crucial role in the effects of probiotic treatment following ovarian cancer surgery (Fig. 2B). Fig. 2Metabolic pathways analysis during probiotic treatment after ovarian cancer surgery. A MetaCyc metabolic pathway analysis. B Differential analysis of metabolic pathways Metabolic pathways analysis during probiotic treatment after ovarian cancer surgery. A MetaCyc metabolic pathway analysis. B Differential analysis of metabolic pathways Probiotic treatment alleviates intestinal inflammation in postoperative ovarian cancer mice To further investigate the beneficial effects of probiotics on intestinal inflammation after ovarian cancer surgery, we established an ovarian cancer mouse model and performed surgical treatment. First, we examined the expression of the intestinal permeability marker FD4 in postoperative mice. The results showed that, compared with the model group, probiotic treatment significantly reduced FD4 levels in the blood of mice, indicating that probiotics restored intestinal permeability in ovarian cancer mice (Fig. 3A). Next, we measured the expression of inflammatory cytokines IL-4, IL-10, IL-6, and TNF-α in the blood of mice. Compared with the model group, probiotic administration effectively reversed the levels of anti-inflammatory cytokines IL-4 and IL-10 in the colon tissue (Fig. 3B, C), while simultaneously reducing the expression of pro-inflammatory cytokines IL-6 and TNF-α (Fig. 3D, E). Additionally, H&E staining was used to analyze inflammation in the intestinal tissue of mice. The results demonstrated that probiotic treatment effectively alleviated intestinal inflammation in ovarian cancer mice (Fig. 3F). Fig. 3Detection of intestinal inflammation in mice after probiotic treatment following ovarian cancer surgery. A Measurement of FD4 expression in mouse serum. B–E. ELISA detection of IL-4, IL-10, TNF-α, and IL-6 expression in mouse intestinal tissues. F H&E staining analysis of intestinal inflammation in mice. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ##P < 0.01, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment Detection of intestinal inflammation in mice after probiotic treatment following ovarian cancer surgery. A Measurement of FD4 expression in mouse serum. B–E. ELISA detection of IL-4, IL-10, TNF-α, and IL-6 expression in mouse intestinal tissues. F H&E staining analysis of intestinal inflammation in mice. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ##P < 0.01, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment Probiotic treatment administered after ovarian cancer surgery in mice can activate the ω-oxidation pathway Previously, we found that the ω-oxidation signaling pathway may play an important role in ovarian cancer patients after probiotic treatment. ω-oxidation is a special form of fatty acid oxidation catalyzed by the monooxygenase system in liver microsomes. Studies have shown that PPARα can effectively activate the ω-oxidation pathway, and CYP4F3 and CYP4A10 are among the key enzymes involved in this oxidation pathway (Christmas et al. 1999; Khalil et al. 2022). Therefore, we examined the expression of these proteins in mice treated with probiotics. qPCR results showed that, compared with the model group, the expression levels of PPARα, CYP4F3, and CYP4A10 in the intestinal tissues of probiotic-treated mice were significantly increased (Fig. 4A–C). Moreover, Western blot analysis also demonstrated a significant upregulation of PPARα, CYP4F3, and CYP4A10 expression after probiotic administration (Fig. 4D, S2A–C). Additionally, we measured the levels of ROS and MDA, which reflect oxidative damage in intestinal tissues. The results showed that, compared with the model group, MDA content in the intestinal tissues of probiotic-treated mice was significantly reduced (Fig. 4E), and ROS levels were also significantly decreased (Fig. 4F, S2D). These findings indicate that probiotic treatment effectively alleviated intestinal tissue damage in ovarian cancer mice after surgery. Fig. 4Expression of ω-oxidation-related molecules in mice after probiotic treatment following ovarian cancer surgery. A–C qPCR analysis of PPARα, CYP4F3, and CYP4A10 mRNA expression in mouse intestinal tissues. D Western blot detection of PPARα, CYP4F3, and CYP4A10 protein expression. E Measurement of MDA content in mouse intestinal tissues. F Flow cytometry analysis of ROS levels in mouse intestinal tissues. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment Expression of ω-oxidation-related molecules in mice after probiotic treatment following ovarian cancer surgery. A–C qPCR analysis of PPARα, CYP4F3, and CYP4A10 mRNA expression in mouse intestinal tissues. D Western blot detection of PPARα, CYP4F3, and CYP4A10 protein expression. E Measurement of MDA content in mouse intestinal tissues. F Flow cytometry analysis of ROS levels in mouse intestinal tissues. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment SCFAs synergize with probiotic combination treatment to activate ω-oxidation signaling Studies have demonstrated that SCFAs can effectively activate the ω-oxidation signaling pathway (Schumann et al. 1978). Here, we further investigated whether the ω-oxidation pathway activated by probiotic treatment is associated with SCFA metabolism. Ovarian cancer mice were treated concurrently with probiotics and SCFAs. The results showed that, compared to the probiotic-only group, combined probiotic and SCFA treatment significantly reduced FD4 levels in mouse serum (Fig. 5A), increased the expression of anti-inflammatory cytokines IL-4 and IL-10 in intestinal tissues (Fig. 5B, C), and markedly decreased the expression of pro-inflammatory cytokines IL-6 and TNF-α (Fig. 5D, E). Moreover, H&E staining revealed a substantial alleviation of intestinal inflammation following the combined treatment (Fig. 5F). These findings indicate that probiotic therapy effectively ameliorates intestinal inflammation and restores intestinal permeability in postoperative ovarian cancer mice. Fig. 5Effects of combined probiotic and SCFA treatment on intestinal homeostasis in postoperative ovarian cancer mice. A Detection of FD4 expression in mouse serum. B–E qPCR analysis of IL-4, IL-10, TNF-α, and IL-6 expression in mouse intestinal tissues. F H&E staining analysis of intestinal inflammation. vs. Control, **P < 0.01, ****P < 0.0001; vs. Model Group, ###P < 0.001, ####P < 0.0001; vs. Probiotic Group, &P < 0.05, &&P < 0.01, n = 5 Effects of combined probiotic and SCFA treatment on intestinal homeostasis in postoperative ovarian cancer mice. A Detection of FD4 expression in mouse serum. B–E qPCR analysis of IL-4, IL-10, TNF-α, and IL-6 expression in mouse intestinal tissues. F H&E staining analysis of intestinal inflammation. vs. Control, **P < 0.01, ****P < 0.0001; vs. Model Group, ###P < 0.001, ####P < 0.0001; vs. Probiotic Group, &P < 0.05, &&P < 0.01, n = 5 Further analysis of ω-oxidation-related molecules in intestinal tissues demonstrated that, relative to the probiotic group, the combined probiotic and SCFA treatment group exhibited significant upregulation of PPARα, CYP4F3, and CYP4A10 at both the mRNA (Fig. 6A–C) and protein levels (Fig. 6D, H). Additionally, measurements of oxidative stress markers revealed that combined treatment significantly reduced the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) in intestinal tissues (Fig. 6E–G). These results suggest that SCFAs play a crucial role in activating the ω-oxidation pathway and restoring intestinal homeostasis in ovarian cancer mice following probiotic treatment. Fig. 6Expression of ω-oxidation-related molecules in mice after probiotic treatment following ovarian cancer surgery. A–C qPCR analysis of PPARα, CYP4F3, and CYP4A10 mRNA expression in mouse intestinal tissues. D Western blot detection of PPARα, CYP4F3, and CYP4A10 protein expression. E Measurement of MDA content in mouse intestinal tissues. F Flow cytometry analysis of ROS levels in mouse intestinal tissues. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment Expression of ω-oxidation-related molecules in mice after probiotic treatment following ovarian cancer surgery. A–C qPCR analysis of PPARα, CYP4F3, and CYP4A10 mRNA expression in mouse intestinal tissues. D Western blot detection of PPARα, CYP4F3, and CYP4A10 protein expression. E Measurement of MDA content in mouse intestinal tissues. F Flow cytometry analysis of ROS levels in mouse intestinal tissues. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, #P < 0.05, ###P < 0.001, n = 5. Model Group: ovarian cancer surgery without probiotic treatment; Probiotic Group: ovarian cancer surgery with probiotic treatment Discussion The gut microbiota is increasingly recognized as a critical regulator of intestinal homeostasis and immune function, particularly in patients undergoing surgical interventions such as ovarian cancer resection (Bock et al. 2022). Surgical stress disrupts microbial communities, often resulting in increased intestinal permeability and inflammation, which can negatively affect postoperative recovery (Guyton and Alverdy 2017). Probiotics, as modulators of the microbiome, have been explored for their capacity to restore microbial balance and reduce inflammation in various clinical settings (Kim et al. 2019). In this study, probiotic treatment led to significant modulation of gut microbiota composition, with enrichment of beneficial genera such as Lactobacillus and Bifidobacterium, along with suppression of potentially pathogenic bacteria. Similar microbial shifts have been observed in other contexts where probiotics promote host health by reshaping gut communities (Singh et al. 2023).Functional analyses highlighted the upregulation of the ω-oxidation pathway following probiotic administration. This metabolic route, regulated by PPARα and involving CYP4F enzymes, plays a role in fatty acid catabolism and protection against oxidative stress (Cheng et al. 2014). The observed increases in PPARα, CYP4F3, and CYP4A10 expression, together with reductions in oxidative damage markers (ROS and MDA), align with evidence that activation of PPARα signaling confers anti-inflammatory and mucosal protective effects in the intestine. Moreover, probiotic treatment enhanced intestinal barrier integrity, as indicated by decreased FD4 permeability, and modulated inflammatory cytokines by elevating anti-inflammatory IL-4 and IL-10, while suppressing pro-inflammatory IL-6 and TNF-α. Such immunomodulatory effects are well-documented in probiotic research, where attenuation of gut inflammation supports tissue repair and barrier function (Cristofori et al. 2021). The synergistic effect observed with co-administration of SCFAs and probiotics further underscores the importance of microbial metabolites in gut health. SCFAs are known to regulate PPAR signaling pathways and exert anti-inflammatory effects that reinforce barrier function (Li et al. 2025). Their combination with probiotics resulted in amplified activation of ω-oxidation-related molecules and more pronounced reductions in oxidative stress and inflammation, suggesting that SCFAs potentiate the therapeutic benefits of probiotic intervention (Markowiak-Kopeć and Śliżewska 2020). Collectively, these findings highlight a novel mechanism by which probiotics, particularly when combined with SCFAs, restore intestinal homeostasis post-ovarian cancer surgery through ω-oxidation activation and attenuation of oxidative and inflammatory damage. This work provides a foundation for future clinical translation and optimization of microbiota-targeted therapies. Limitations and prospects This study has several limitations. First, the small clinical sample size limits the generalizability and statistical power of the findings. Future studies with larger patient cohorts are needed to enhance the applicability and reliability of the results. Second, although a mouse model was used, it cannot fully replicate the complex postoperative physiology of humans, particularly in terms of gut microbiota and metabolic functions. Therefore, the findings may not completely reflect clinical realities. While animal models provide valuable preliminary data, future research should incorporate more clinical data to validate these findings in real-world settings. Furthermore, although we identified PPARα-mediated activation of the ω-oxidation pathway, other underlying molecular mechanisms remain unclear, and the combined effects of probiotics and SCFAs require further investigation. Future studies should delve deeper into these mechanisms to optimize therapeutic strategies. Overall, our results suggest that combining probiotics with SCFAs to modulate ω-oxidation could be a promising approach for restoring intestinal homeostasis following ovarian cancer surgery. However, broader clinical trials and more detailed mechanistic studies are necessary to validate its efficacy and optimize treatment protocols for patient benefit. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file 1: S1 Analysis of differences in gut microbiota before and after probiotic treatment in patients. A. Alpha diversity analysis. B. Beta diversity analysis. BT, Before treatment; AT, After treatmentSupplementary Material 1 Supplementary file 1: S1 Analysis of differences in gut microbiota before and after probiotic treatment in patients. A. Alpha diversity analysis. B. Beta diversity analysis. BT, Before treatment; AT, After treatment Supplementary Material 1 Supplementary file 2: S2 A-C. Quantitative analysis of PPARα, CYP4F3, and CYP4A10 protein levels. D. Quantitative analysis of DCFH fluorescence intensity. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, ###P < 0.001, ####P < 0.0001, n = 5Supplementary Material 2 Supplementary file 2: S2 A-C. Quantitative analysis of PPARα, CYP4F3, and CYP4A10 protein levels. D. Quantitative analysis of DCFH fluorescence intensity. vs. Control, ***P < 0.001, ****P < 0.0001; vs. Model Group, ###P < 0.001, ####P < 0.0001, n = 5 Supplementary Material 2